Content about Ranibizumab

August 13, 2012
FDA approves Genentech's Lucentis for diabetic macular edema

Regulators have approved a biotech drug made by Genentech for treating a complication related to diabetes.

SILVER SPRING, Md. — Regulators have approved a biotech drug made by Genentech for treating a complication related to diabetes.

The Food and Drug Administration approved Lucentis (ranibizumab) for diabetic macular edema, a cause of vision loss in people with diabetes. The drug already was approved for age-related macular degeneration.

July 27, 2012
FDA panel recommends new approval for Genentech eye drug

A panel of Food and Drug Administration experts is recommending the approval of a drug made by Genentech for diabetic macular edema, the company said.

SILVER SPRING, Md. — A panel of Food and Drug Administration experts is recommending the approval of a drug made by Genentech for diabetic macular edema, the company said.

February 11, 2011
Lucentis improves vision among diabetes patients in trial

Genentech, a subsidiary of Roche, reported that its eye drug helped improve vision in patients suffering from a complication caused by diabetes.

SOUTH SAN FRANCISCO, Calif. — Genentech, a subsidiary of Roche, reported that its eye drug helped improve vision in patients suffering from a complication caused by diabetes.

In its phase-3 RISE study, Genentech said diabetic macular edema patients that received monthly Lucentis (ranibizumab injection) achieved an improvement in vision at 24 months, compared with placebo.

August 31, 2010
FDA expedites review of Alimera's Iluvien

The Food and Drug Administration has granted priority review for a diabetic macular edema treatment....

ATLANTA The Food and Drug Administration has granted priority review for a diabetic macular edema treatment.

August 25, 2010
Novartis completes purchase of Alcon stock

Novartis on Thursday announced that it has completed its purchase of Alcon stock from Nestle,...

BASEL, Switzerland Novartis on Thursday announced that it has completed its purchase of Alcon stock from Nestle, resulting in 77% ownership of Alcon. This has been achieved by completing the acquisition of the remaining 52% of Alcon shares owned by Nestle for a total of $28.3 billion.

 

June 22, 2010
FDA approves Lucentis for vision loss-related disease

The Food and Drug Administration has approved a drug made by Genentech for treating a...

May 2, 2010
Study: Combination therapy may improve diabetic macular edema

A combination of a biotech drug and laser treatment may improve vision in patients with...